Upstream Bio opened lower at $3.13, compared with its previous close of $3.20. In the last trading session, the stock traded between $2.80 and $3.13. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Upstream Bio is now worth
$ 12.98
Resulting in a loss of
$ 87.02 (87.02%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
75%
Hold
25%
Sell
0%
Markets Today
Today's Change
$-0.34 (-10.75%)
Day High
$3.13
Day Low
$2.80
Day Open
$3.13
Prev Close
$3.20
Volume
22,77,866
1W Return
-22.89%
1M Return
-31.40%
3M Return
-59.66%
6M Return
-68.65%
1Y Return
-87.99%
Fundamentals
Market Cap ($ Mn)
157
PE Ratio
-
PB Ratio
1.35
PEG Ratio
-
ROE
-35.11%
ROCE
-39.18%
EPS (TTM)
-
Investment Returns
1 Week
-22.89%
1 Month
-31.40%
3 Months
-59.66%
6 Months
-68.65%
9 Months
-80.56%
Financials
Quarterly
All values in $ Mn
0.9
Jun 25
0.7
Sep 25
0.7
Dec 25
1.0
Mar 26
0.8
Jun 26
0.4
Sep 26
Updates
8Sep
Upstream Bio verekitug cuts asthma exacerbations by 56% in Phase 2 trial
Verekitug reduced annualized asthma exacerbation rates by 56% vs placebo in Phase 2. Improvements seen in lung function (FEV1) and inflammatory biomarkers as early as week 2. Company plans to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027. Long-term extension study retained over 90% of eligible patients from Phase 2 trial.
2mo ago
2Sep
HC Wainwright reiterates Buy on Upstream Bio at $36 target
HC Wainwright & Co. reiterates Buy rating on Upstream Bio (NASDAQ: UPB). Price target maintained at $36 per share. Analyst Matthew Caufield issued the update. No change in valuation stance or target price.
2mo ago
1Sep
Upstream Bio plans Phase 3 trials for verekitug in asthma, CRSwNP
Upstream Bio plans Phase 3 trials for verekitug in severe asthma and CRSwNP starting Q1 2027. Trials will use a 400 mg dose every 12 weeks across approximately 1,500 patients. Primary endpoints include AAER for asthma and nasal scores for CRSwNP over 48 weeks. Verekitug targets the TSLP receptor, building on data from over 500 treated patients. Potential FDA BLA submission could lead to a launch as early as 2030.
2mo ago
14Jun
Upstream Bio reports positive verekitug trial data in CRSwNP
Upstream Bio announced positive responder analyses from the Phase 2 VIBRANT trial, showing verekitug achieved clinically meaningful improvements in nasal polyp score in 79% of participants. The drug also demonstrated significant efficacy across key secondary endpoints, including nasal congestion and total symptom score. Upstream Bio plans to initiate Phase 3 trials for CRSwNP and severe asthma in the first quarter of 2027.
5mo ago
12Jun
JP Morgan downgrades Upstream Bio to Neutral, cuts target to $8
JP Morgan analyst Tessa Romero downgraded Upstream Bio from Overweight to Neutral and lowered the price target from $35 to $8.
